Multiple System Atrophy Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Multiple System Atrophy remains an active clinical development field. The field is increasingly separating symptomatic benefit from disease modification, while enrichment, digital measures and fluid or imaging biomarkers reshape trial design. The PatSnap evidence set used here contains 163 matched trial records and 35 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07657520 | Intervention not normalized | Not Applicable; Recruiting | West China Hospital | China | Incidence of Multiple System Atrophy (MSA) at 12 Months (Baseline to Month 12) | 2027-07-30 |
| JPRN-jRCT1030260227 | Intervention not normalized | Not Applicable; 募集中 | Sponsor not listed | Japan | Lower limb muscle strength; 下肢筋力値 | 2027-03-31 |
| NCT07644013 | Intervention not normalized | Not Applicable; Recruiting | Peking University First Hospital | China | Change in disease severity (Baseline to up to 36 months after enrollment.) | 2029-12-31 |
| NCT07640542 | [11C]MODAG 005 | Early Phase 1; Not yet recruiting | MODAG GmbH | Geography not listed | Safety and Tolerability (Inclusion to 4 days (± 2 days) post injection.); Safety and tolerability (Inclusion to 4 days (± 2 days) post injection.) | 2027-07-01 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple System Atrophy (Phase 2): the indexed record reports Change From Baseline in Modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I Total Score at Week 52(Least Squares Mean) = 5.58 score on a scale (Standard Error, 0.64); Change From Baseline in Modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I Total Score at Week 52(Least Squares Mean): Least Square (LS) Mean Difference = -0.04(95% CI, -1.78 to 1.69), P-Value = 0.961; Change From Baseline in Modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I Total Score at Week 52(Least Squares Mean): Least Square (LS) Mean Difference = -0.04(95% CI, -1.78 to 1.69), P-Value = 0.961.
- Efficacy and Safety Study of Vatiquinone for the Treatment of Mitochondrial Disease Subjects With Refractory Epilepsy (Phase 2/3): the indexed record reports Percent Change From Baseline to Week 24 in the Number of Observable Motor Seizures Per 28 Days During the Double-blind Period(Median) = -0.33 percent change (95% Confidence Interval, -28.97 to 17.06); Percent Change From Baseline to Week 24 in the Number of Observable Motor Seizures Per 28 Days During the Double-blind Period(Median): Median Difference (Final Values) = -8.31(95% CI, -31.3 to 16.4), P-Value = 0.173; Percent Change From Baseline to Week 24 in the Number of Observable Motor Seizures Per 28 Days During the Double-blind Period(Median): Median Difference (Final Values) = -8.31(95% CI, -31.3 to 16.4), P-Value = 0.173.
- Ono Announces Encouraging Efficacy Signals of ONO-2808, a S1P5 Receptor Agonist, in an interim analysis of Ongoing Phase 2 Clinical Trial in Patients with Multiple System Atrophy (Phase 2): the indexed record reports UMSARS = the progression of MSA tended to be slower in the ONO-2808 group; UMSARS = the progression of MSA tended to be slower in the ONO-2808 group.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including [11C]MODAG 005 (Early Phase 1). Company & Deal Intelligence records identify sponsor context for West China Hospital, Peking University First Hospital, MODAG GmbH. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Validated biomarkers that bridge biological activity to meaningful function.
- Longer follow-up that distinguishes transient symptom change from altered disease trajectory.
- Decentralized and digital measures that reduce noise without increasing patient burden.
- Trials designed around genetically or biologically defined subgroups.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Multiple System Atrophy has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
